[go: up one dir, main page]

WO2008078727A1 - Pharmaceutical composition having improved dissolution property - Google Patents

Pharmaceutical composition having improved dissolution property Download PDF

Info

Publication number
WO2008078727A1
WO2008078727A1 PCT/JP2007/074782 JP2007074782W WO2008078727A1 WO 2008078727 A1 WO2008078727 A1 WO 2008078727A1 JP 2007074782 W JP2007074782 W JP 2007074782W WO 2008078727 A1 WO2008078727 A1 WO 2008078727A1
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
improved dissolution
dissolution property
azelnidipine
olmesartan medoxomil
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2007/074782
Other languages
French (fr)
Japanese (ja)
Inventor
Shuichi Yada
Mitsuru Kanno
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Daiichi Sankyo Co Ltd
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Priority to JP2008551105A priority Critical patent/JP5241511B2/en
Publication of WO2008078727A1 publication Critical patent/WO2008078727A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Disclosed is a pharmaceutical composition having improved dissolution property, which contains olmesartan medoxomil and azelnidipine. Specifically disclosed is a pharmaceutical composition containing (A) olmesartan medoxomil, (B) azelnidipine and (C) a polyvinyl alcohol or a vinyl alcohol copolymer.
PCT/JP2007/074782 2006-12-26 2007-12-25 Pharmaceutical composition having improved dissolution property Ceased WO2008078727A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2008551105A JP5241511B2 (en) 2006-12-26 2007-12-25 Pharmaceutical composition with improved dissolution

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006-349473 2006-12-26
JP2006349473 2006-12-26

Publications (1)

Publication Number Publication Date
WO2008078727A1 true WO2008078727A1 (en) 2008-07-03

Family

ID=39562516

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2007/074782 Ceased WO2008078727A1 (en) 2006-12-26 2007-12-25 Pharmaceutical composition having improved dissolution property

Country Status (4)

Country Link
JP (1) JP5241511B2 (en)
KR (1) KR20090094287A (en)
TW (1) TWI414310B (en)
WO (1) WO2008078727A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010038695A1 (en) * 2008-09-30 2010-04-08 大洋薬品工業株式会社 Compression-molded preparation and method for producing the same
JP2011207873A (en) * 2010-03-10 2011-10-20 Dainippon Sumitomo Pharma Co Ltd Pharmaceutical composition containing irbesartan and amlodipine or salt of the same
JP2014080418A (en) * 2012-09-27 2014-05-08 Sanwa Kagaku Kenkyusho Co Ltd Solid pharmaceutical preparation containing anagliptin or salt thereof

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101148884B1 (en) * 2010-02-01 2012-05-29 동성제약주식회사 Composition for prevention or treatment hypertension comprising olmesartan medoxomil with an increased dissolution rate

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002034263A1 (en) * 2000-10-25 2002-05-02 Takeda Chemical Industries, Ltd. Preventives/remedies for portal hypertension
WO2004067003A1 (en) * 2003-01-31 2004-08-12 Sankyo Company, Limited Medicine for prevention of and treatment for arteriosclerosis and hypertension
CN1762354A (en) * 2004-10-18 2006-04-26 上海药明康德新药开发有限公司 A stable pharmaceutical composition containing a calcium blocker
WO2006123765A1 (en) * 2005-05-20 2006-11-23 Daiichi Sankyo Company, Limited Film coated preparation
WO2006123766A1 (en) * 2005-05-20 2006-11-23 Daichi Sankyo Company, Limited Film coated preparation containing dextrose
WO2006138421A2 (en) * 2005-06-15 2006-12-28 Elan Pharma International Limited Nanoparticulate azelnidipine formulations
WO2007001066A1 (en) * 2005-06-27 2007-01-04 Daiichi Sankyo Company, Limited Pharmaceutical preparation containing an angiotensin ii receptor antagonist and a calcium channel blocker

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007001067A2 (en) * 2005-06-27 2007-01-04 Daiichi Sankyo Company, Limited Solid dosage form comprising an angiotensin ii receptor antagonist and a calcium channel blocker
JP5063370B2 (en) * 2005-06-27 2012-10-31 第一三共株式会社 Method for preparing wet granulated pharmaceutical

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002034263A1 (en) * 2000-10-25 2002-05-02 Takeda Chemical Industries, Ltd. Preventives/remedies for portal hypertension
WO2004067003A1 (en) * 2003-01-31 2004-08-12 Sankyo Company, Limited Medicine for prevention of and treatment for arteriosclerosis and hypertension
CN1762354A (en) * 2004-10-18 2006-04-26 上海药明康德新药开发有限公司 A stable pharmaceutical composition containing a calcium blocker
WO2006123765A1 (en) * 2005-05-20 2006-11-23 Daiichi Sankyo Company, Limited Film coated preparation
WO2006123766A1 (en) * 2005-05-20 2006-11-23 Daichi Sankyo Company, Limited Film coated preparation containing dextrose
WO2006138421A2 (en) * 2005-06-15 2006-12-28 Elan Pharma International Limited Nanoparticulate azelnidipine formulations
WO2007001066A1 (en) * 2005-06-27 2007-01-04 Daiichi Sankyo Company, Limited Pharmaceutical preparation containing an angiotensin ii receptor antagonist and a calcium channel blocker

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JAPAN PHARMACEUTICAL EXCIPIENTS COUNCIL: "Igakuhin Tenkabutsu Jiten", vol. 1ST ED., 1994, KABUSHIKI KAISHA YAKUJI NIPPOSHA HAKKO, pages: 124 *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010038695A1 (en) * 2008-09-30 2010-04-08 大洋薬品工業株式会社 Compression-molded preparation and method for producing the same
JPWO2010038695A1 (en) * 2008-09-30 2012-03-01 大洋薬品工業株式会社 COMPRESSION MOLDED PREPARATION AND METHOD FOR PRODUCING THE SAME
JP2011207873A (en) * 2010-03-10 2011-10-20 Dainippon Sumitomo Pharma Co Ltd Pharmaceutical composition containing irbesartan and amlodipine or salt of the same
JP2014055173A (en) * 2010-03-10 2014-03-27 Dainippon Sumitomo Pharma Co Ltd Pharmaceutical composition containing irbesartan and amlodipine or salt thereof
JP2015221826A (en) * 2010-03-10 2015-12-10 大日本住友製薬株式会社 Pharmaceutical composition containing irbesartan and amlodipine or salt thereof
JP2017052785A (en) * 2010-03-10 2017-03-16 大日本住友製薬株式会社 Pharmaceutical composition containing irbesartan and amlodipine or salt thereof
JP2018035202A (en) * 2010-03-10 2018-03-08 大日本住友製薬株式会社 Pharmaceutical composition containing irbesartan and amlodipine or salt thereof
JP2019069981A (en) * 2010-03-10 2019-05-09 大日本住友製薬株式会社 Pharmaceutical composition containing irbesartan and amlodipine or salt thereof
JP2020094064A (en) * 2010-03-10 2020-06-18 大日本住友製薬株式会社 Pharmaceutical composition containing irbesartan and amlodipine or salt thereof
JP2014080418A (en) * 2012-09-27 2014-05-08 Sanwa Kagaku Kenkyusho Co Ltd Solid pharmaceutical preparation containing anagliptin or salt thereof

Also Published As

Publication number Publication date
JPWO2008078727A1 (en) 2010-04-30
TW200833359A (en) 2008-08-16
TWI414310B (en) 2013-11-11
JP5241511B2 (en) 2013-07-17
KR20090094287A (en) 2009-09-04

Similar Documents

Publication Publication Date Title
WO2007010034A3 (en) Ampholytic copolymer, production thereof, and use of the same
BRPI0716171A2 (en) compound, pharmaceutical composition and use of a compound.
WO2008115281A3 (en) Compounds for treating viral infections
WO2009057569A1 (en) Film-coated preparation
WO2008127364A3 (en) Antiviral compounds and use thereof
MY161465A (en) Seed treatment formulations and methods of use
GB2454620A (en) Solid dosage form of olmesartan medoxomil and amlodipine
WO2008153610A3 (en) Use of il-23 antagonists for treatment of infection
TW200833372A (en) Use of (meth)acrylate copolymers in delayed-release pharmaceutical forms for decreasing the influence of ethanol on the release of active compound
WO2009023662A3 (en) Water-resistant, rub-resistant, sprayable, homogeneous sunscreen composition
WO2008008495A3 (en) Stereocomplex-forming composition and implantable medical device comprising same
WO2007099171A3 (en) Bicyclo-pyrazoles active as kinase inhibitors
WO2005118831A3 (en) Polymeric compositions and related methods of use
BRPI0720314A2 (en) COMPOSITION, AND, USES OF A Triazole COMPOSITION AND COMPOSITION.
WO2008078727A1 (en) Pharmaceutical composition having improved dissolution property
WO2008093247A3 (en) Medicament for the treatment of endometriosis
WO2008078726A1 (en) Solid preparation
WO2008054484A3 (en) Compositions, materials incorporating the compositions, and methods of using the compositions and materials
WO2008078729A1 (en) Method for improving dissolution property
WO2008078728A1 (en) Ascorbic acid-containing pharmaceutical composition
WO2009109990A3 (en) Pramipexole composition comprising sugar alcohol(s)
WO2007093168A3 (en) Rapid release irbesartan-containing pharmaceutical composition
WO2009143403A8 (en) Combination therapy for the management hypertension
GB201018110D0 (en) Solid dosage form of olmesartan medoxomil, amiodipine and hydrochlorothiazide
WO2008068727A3 (en) Pharmaceutical composition comprising candesartan cilexetil

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07860011

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2008551105

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 1020097012660

Country of ref document: KR

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07860011

Country of ref document: EP

Kind code of ref document: A1